Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer

Cytokine and Growth Factor Reviews

Volumn 26, Issue 5, 2015, Pages 489-498

  Johnstone, Cameron N ^a,b,c   Chand, Ashwini ^a,b   Putoczki, Tracy L ^d,e   Ernst, Matthias ^a,b  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer; IL 11; IL 6; Interleukin; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR ALPHA; FOCAL ADHESION KINASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 11 RECEPTOR ALPHA; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; MUTEIN; NVP BSK 805; ONCOSTATIN M; PARATHYROID HORMONE RELATED PROTEIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; SILTUXIMAB; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN D; IL11 PROTEIN, HUMAN; TUMOR PROTEIN;

APOPTOSIS; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CELL HETEROGENEITY; CELL PROLIFERATION; DOWN REGULATION; GENE TARGETING; HUMAN; INTRADUCTAL CARCINOMA; LIGAND BINDING; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; MORTALITY; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-11; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84941935471     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.015     Document Type: Short Survey

References (120)

1. Ernst M., Putoczki T.L. Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancers. Clin. Cancer Res. 2014, 20:5579-5588.
2. Putoczki T.L., Ernst M. IL-11 signaling as a therapeutic target for cancer. Immunotherapy 2015, 7:441-453.
3. Stumhofer J.S., Tait E.D., Quinn W.J., Hosken N., Spudy B., Goenka R., et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 2010, 11:1119-1126.
4. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
5. Dillon S.R., Sprecher C., Hammond A., Bilsborough J., Rosenfeld-Franklin M., Presnell S.R., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004, 5:752-760.
6. Elson G.C., Lelievre E., Guillet C., Chevalier S., Plun-Favreau H., Froger J., et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 2000, 3:867-872.
7. Pennica D., King K.L., Shaw K.J., Luis E., Rullamas J., Luoh S.M., et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1142-1146.
8. Rose T.M., Bruce A.G. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:8641-8645.
9. Gearing D.P., Gough N.M., King J.A., Hilton D.J., Nicola N.A., Simpson R.J., et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 1987, 6:3995-4002.
10. Paul S.R., Bennett F., Calvetti J.A., Kelleher K., Wood C.R., O'Hara R.M., et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7512-7516.
11. Silver J.S., Hunter C.A. gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 2010, 88:1145-1156.
12. Ernst M., Jenkins B.J. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004, 20:23-32.
13. Putoczki T.L., Dobson R.C., Griffin M.D. The structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6. Acta Crystallogr. D: Biol. Crystallogr. 2014, 70:2277-2285.
14. Yin T., Yasukawa K., Taga T., Kishimoto T., Yang Y.C. Identification of a 130-kilodalton tyrosine-phosphorylated protein induced by interleukin-11 as JAK2 tyrosine kinase, which associates with gp130 signal transducer. Exp. Hematol. 1994, 22:467-472.
15. Orazi A., Du X., Yang Z., Kashai M., Williams D.A. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. 1996, 75:33-42.
16. Weich N.S., Wang A., Fitzgerald M., Neben T.Y., Donaldson D., Giannotti J., et al. Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood 1997, 90:3893-3902.
17. Tepler I., Elias L., Smith J.W., 2nd, Hussein M., Rosen G., Chang A.Y., et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87:3607-3614.
18. Gordon M.S., McCaskill-Stevens W.J., Battiato L.A., Loewy J., Loesch D., Breeden E., et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996, 87:3615-3624.
19. Wu S., Zhang Y., Xu L., Dai Y., Teng Y., Ma S., et al. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support Care Cancer 2012, 20:1875-1884.
20. Kaye J.A. Clinical development of recombinant human interleukin-11 to treat chemotherapy-induced thrombocytopenia. Curr. Opin. Hematol. 1996, 3:209-215.
21. Robb L., Li R., Hartley L., Nandurkar H.H., Koentgen F., Begley C.G. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat. Med. 1998, 4:303-308.
22. Putoczki T.L., Thiem S., Loving A., Busuttil R.A., Wilson N.J., Ziegler P.K., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271.
23. Robb L., Hilton D.J., Willson T.A., Begley C.G. Structural analysis of the gene encoding the murine interleukin-11 receptor alpha-chain and a related locus. J. Biol. Chem. 1996, 271:13754-13761.
24. Grotzinger J., Kernebeck T., Kallen K.J., Rose-John S. IL-6 type cytokine receptor complexes: hexamer, tetramer or both?. Biol. Chem. 1999, 380:803-813.
25. Matadeen R., Hon W.C., Heath J.K., Jones E.Y., Fuller S. The dynamics of signal triggering in a gp130-receptor complex. Structure 2007, 15:441-448.
26. Jenkins B.J., Grail D., Nheu T., Najdovska M., Wang B., Waring P., et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat. Med. 2005, 11:845-852.
27. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
28. Jarnicki A., Putoczki T., Ernst M. Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?. Cell Div. 2010, 5:14.
29. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
30. Babon J.J., Varghese L.N., Nicola N.A. Inhibition of IL-6 family cytokines by SOCS3. Semin. Immunol. 2014, 26:13-19.
31. Dance M., Montagner A., Salles J.P., Yart A., Raynal P. The molecular functions of Shp2 in the Ras/mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 2008, 20:453-459.
32. Thiem S., Pierce T.P., Palmieri M., Putoczki T.L., Buchert M., Preaudet A., et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J. Clin. Invest. 2013, 123:767-781.
33. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
34. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
35. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22:571-584.
36. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
37. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 2009, 15:4649-4664.
38. Douglas A.M., Goss G.A., Sutherland R.L., Hilton D.J., Berndt M.C., Nicola N.A., et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997, 14:661-669.
39. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
40. Lacroix M., Siwek B., Marie P.J., Body J.J. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett. 1998, 127:29-35.
41. Crichton M.B., Nichols J.E., Zhao Y., Bulun S.E., Simpson E.R. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol. Cell. Endocrinol. 1996, 118:215-220.
42. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
43. Cancer Genome Atlas N Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
44. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
45. Davidson A.J., Freeman S.A., Crosier K.E., Wood C.R., Crosier P.S. Expression of murine interleukin 11 and its receptor alpha-chain in adult and embryonic tissues. Stem Cells 1997, 15:119-124.
46. Singh B., Berry J.A., Shoher A., Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J. Surg. Res. 2006, 131:267-275.
47. Shi X.Z., Sarna S.K. Transcriptional regulation of inflammatory mediators secreted by human colonic circular smooth muscle cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G274-G284.
48. Stickeler E., Pils D., Klar M., Orlowsk-Volk M., Zur Hausen A., Jager M., et al. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. Oncol. Rep. 2011, 26:1037-1045.
49. Magbanua M.J., Wolf D.M., Yau C., Davis S.E., Crothers J., Au A., et al. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015, 17:73.
50. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
51. Ernst M., Najdovska M., Grail D., Lundgren-May T., Buchert M., Tye H., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 2008, 118:1727-1738.
52. Hanavadi S., Martin T.A., Watkins G., Mansel R.E., Jiang W.G. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann. Surg. Oncol. 2006, 13:802-808.
53. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121:2750-2767.
54. Yu K.D., Zhu R., Zhan M., Rodriguez A.A., Yang W., Wong S., et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin. Cancer Res. 2013, 19:2723-2733.
55. Bockhorn J., Dalton R., Nwachukwu C., Huang S., Prat A., Yee K., et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat. Commun. 2013, 4:1393.
56. Kim G., Ouzounova M., Quraishi A.A., Davis A., Tawakkol N., Clouthier S.G., et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene 2015, 34:671-680.
57. Xiang Z.L., Zeng Z.C., Fan J., Tang Z.Y., Zeng H.Y. Expression of connective tissue growth factor and interleukin-11 in intratumoral tissue is associated with poor survival after curative resection of hepatocellular carcinoma. Mol. Biol. Rep. 2012, 39:6001-6006.
58. Necula L.G., Chivu-Economescu M., Stanciulescu E.L., Bleotu C., Dima S.O., Alexiu I., et al. IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J. Gastrointest. Liver Dis. 2012, 21:23-29.
59. Pan D., Xu L., Liu H., Zhang W., Liu W., Liu Y., et al. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Cancer Sci. 2015, 106:592-597.
60. Gyorffy B., Surowiak P., Budczies J., Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLOS ONE 2013, 8:e82241.
61. Sotiriou C., Lacroix M., Lespagnard L., Larsimont D., Paesmans M., Body J.J. Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett. 2001, 169:87-95.
62. Ren L., Wang X., Dong Z., Liu J., Zhang S. Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway. Med. Oncol. 2013, 30:634.
63. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13:3207-3214.
64. Madden S.F., Clarke C., Gaule P., Aherne S.T., O'Donovan N., Clynes M., et al. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res. 2013, 15:R52.
65. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
66. Jung J.E., Lee H.G., Cho I.H., Chung D.H., Yoon S.H., Yang Y.M., et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005, 19:1296-1298.
67. Onnis B., Fer N., Rapisarda A., Perez V.S., Melillo G. Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J. Clin. Invest. 2013, 123:1615-1629.
68. Marusyk A., Tabassum D.P., Altrock P.M., Almendro V., Michor F., Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 2014, 514:54-58.
69. Mahboubi K., Biedermann B.C., Carroll J.M., Pober J.S. IL-11 activates human endothelial cells to resist immune-mediated injury. J. Immunol. 2000, 164:3837-3846.
70. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3:895-902.
71. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
72. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
73. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
74. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7950-7955.
75. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1397-1402.
76. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
77. Lin L., Hutzen B., Lee H.F., Peng Z., Wang W., Zhao C., et al. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLOS ONE 2013, 8:e82821.
78. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
79. Marotta L.L., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
80. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
81. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012, 47:570-584.
82. Adkins F.C., Gonzalez-Angulo A.M., Lei X., Hernandez-Aya L.F., Mittendorf E.A., Litton J.K., et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann. Surg. Oncol. 2011, 18:3164-3173.
83. Simpson E., Rubin G., Clyne C., Robertson K., O'Donnell L., Jones M., et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol. Metab. 2000, 11:184-188.
84. Miki Y., Suzuki T., Tazawa C., Yamaguchi Y., Kitada K., Honma S., et al. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res. 2007, 67:3945-3954.
85. Agarwal V.R., Bulun S.E., Leitch M., Rohrich R., Simpson E.R. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab. 1996, 81:3843-3849.
86. To S.Q., Knower K.C., Cheung V., Simpson E.R., Clyne C.D. Transcriptional control of local estrogen formation by aromatase in the breast. J. Steroid Biochem. Mol. Biol. 2015, 145:179-186.
87. Simpson E.R., Michael M.D., Agarwal V.R., Hinshelwood M.M., Bulun S.E., Zhao Y. Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J. 1997, 11:29-36.
88. De Miguel F., Lee S.O., Onate S.A., Gao A.C. Stat3 enhances transactivation of steroid hormone receptors. Nucl. Recept. 2003, 1:3.
89. Zhang Z., Jones S., Hagood J.S., Fuentes N.L., Fuller G.M. STAT3 acts as a co-activator of glucocorticoid receptor signaling. J. Biol. Chem. 1997, 272:30607-30610.
90. Morris P.G., Hudis C.A., Giri D., Morrow M., Falcone D.J., Zhou X.K., et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev. Res. 2011, 4:1021-1029.
91. Kang Y., He W., Tulley S., Gupta G.P., Serganova I., Chen C.R., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13909-13914.
92. Yuan J.H., Yang F., Wang F., Ma J.Z., Guo Y.J., Tao Q.F., et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014, 25:666-681.
93. Girasole G., Passeri G., Jilka R.L., Manolagas S.C. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Invest. 1994, 93:1516-1524.
94. Kozlow W., Guise T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol. Neoplasia 2005, 10:169-180.
95. Deckers M., van Dinther M., Buijs J., Que I., Lowik C., van der Pluijm G., et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006, 66:2202-2209.
96. Bellam N., Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat. Res. 2010, 155:85-103.
97. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 2012, 8:1237-1247.
98. Musashi M., Yang Y.C., Paul S.R., Clark S.C., Sudo T., Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:765-769.
99. Kobayashi S., Teramura M., Sugawara I., Oshimi K., Mizoguchi H. Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood 1993, 81:889-893.
100. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11:123-134.
101. Bilinski P., Roopenian D., Gossler A. Maternal IL-11Ralpha function is required for normal decidua and fetoplacental development in mice. Genes Dev. 1998, 12:2234-2243.
102. Nandurkar H.H., Robb L., Tarlinton D., Barnett L., Kontgen F., Begley C.G. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 1997, 90:2148-2159.
103. Lee C.G., Hartl D., Matsuura H., Dunlop F.M., Scotney P.D., Fabri L.J., et al. Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production. Am. J. Respir. Cell. Mol. Biol. 2008, 39:739-746.
104. Kapina M.A., Shepelkova G.S., Avdeenko V.G., Guseva A.N., Kondratieva T.K., Evstifeev V.V., et al. Interleukin-11 drives early lung inflammation during Mycobacterium tuberculosis infection in genetically susceptible mice. PLoS ONE 2011, 6:e21878.
105. Xu S., Neamati N. gp130: a promising drug target for cancer therapy. Expert Opin. Ther. Targets 2013, 17:1303-1328.
106. Yoshida K., Taga T., Saito M., Suematsu S., Kumanogoh A., Tanaka T., et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:407-411.
107. Sommer J., Effenberger T., Volpi E., Waetzig G.H., Bernhardt M., Suthaus J., et al. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J. Biol. Chem. 2012, 287:13743-13751.
108. Huang G., Yu L., Cooper L.J., Hollomon M., Huls H., Kleinerman E.S. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012, 72:271-281.
109. Arap W., Kolonin M.G., Trepel M., Lahdenranta J., Cardo-Vila M., Giordano R.J., et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 2002, 8:121-127.
110. Zurita A.J., Troncoso P., Cardo-Vila M., Logothetis C.J., Pasqualini R., Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res. 2004, 64:435-439.
111. Pasqualini R., Millikan R.E., Christianson D.R., Cardo-Vila M., Driessen W.H., Giordano R.J., et al. Targeting the interleukin-11 receptor alpha in metastatic prostate cancer: a first-in-man study. Cancer 2015, 121:2411-2421.
112. Lewis V.O., Ozawa M.G., Deavers M.T., Wang G., Shintani T., Arap W., et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res. 2009, 69:1995-1999.
113. Buchert M., Burns C.J., Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 2015, May 18 [Epub ahead of print] Review. PMID: 25982279. 10.1038/onc.2015.150.
114. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012, 119:2721-2730.
115. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J., et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011, 365:689-698.
116. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., et al. Endostatin's antiangiogenic signaling network. Mol. Cell 2004, 13:649-663.
117. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
118. Buffa F.M., Camps C., Winchester L., Snell C.E., Gee H.E., Sheldon H., et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011, 71:5635-5645.
119. Gluck S., Ross J.S., Royce M., McKenna E.F., Perou C.M., Avisar E., et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/- trastuzumab. Breast Cancer Res. Treat. 2012, 132:781-791.
120. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.